Katapult Holdings' P/S remains below industry median despite share price surge due to its lower forecast growth. Investors see limited potential for revenue improvement, requiring a change of fortune for a higher P/S ratio.
Despite Katapult Holdings' recent share price increase, its P/S ratio still trails most other firms due to a weaker revenue outlook. Investors accept this as they don't foresee any significant future revenue surprises. A turn of luck is needed for a higher P/S justification.
$Katapult(KPLT.US)$I can't believe I'm the only one over here sitting on this rocket
1
举报
MyMoo6293 :
The rocket doesn't seem to have been successful in taking off...it came down in a rather dramatic way. I am getting in now that it is making a turnaround.
Gainers: •$Veru Inc(VERU.US)$+25.8% (announces that in a Pre-EUA meeting held May 10 2022 FDA has agreed that the efficacy and safety data from the completed Phase 3 clinical study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome are sufficient to support the submission of a request for Emergency Use Authorization) •$Desktop Metal(DM.US)$+15.8% (prices offering of $100 mln of 6.0% convertible se...
19
1
6
举报
我只想赚个买菜钱 :
NIO Pre-market UP 3.3%, before open market, immediately turned into RED. Only NIO able to do so. Haha.
Katapult股票讨论区
something very compelling about this chart
Beat Earnings Estimates *again*
近两年营收快速增长,但是营业利润却由于管理费用的激增,2021年下滑43%,净利润下滑6%。
2022前三季度营收大幅下滑29%,管理费用却继续增长,营业利润和净利润均进入亏损区间。
目前看不到任何吸引力。
专栏Today's pre-market stock movers: PTON, NIO, RBLX, U and more
• $Veru Inc(VERU.US)$ +25.8% (announces that in a Pre-EUA meeting held May 10 2022 FDA has agreed that the efficacy and safety data from the completed Phase 3 clinical study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome are sufficient to support the submission of a request for Emergency Use Authorization)
• $Desktop Metal(DM.US)$ +15.8% (prices offering of $100 mln of 6.0% convertible se...
专栏Top upgrades and downgrades on 5/11
• $Arcturus Therapeutics(ARCT.US)$ : Baird Upgrades to Neutral from Underperform - PT $18 (from $21)
• $Arrowhead Pharmaceuticals(ARWR.US)$ : Baird Upgrades to Outperform from Neutral - PT $60 (from $71)
• $Cronos Group(CRON.US)$ : CIBC Upgrades to Outperformer from Neutral
• $HF Sinclair(DINO.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $52 (from $38)
• $8x8(EGHT.US)$ : B. Riley Upgrades to Buy from Neutral - PT $13.50
• $Novanta(NOVT.US)$ : William...
暂无评论